May prevent the growth of new blood vessels that tumors need to grow and may kill cancer cells. It is a type of antiangiogenesis agent and a type of vascular endothelial growth factor (VEGF) receptor tyrosine kinase inhibitor.
June 4, 2020
May prevent the growth of new blood vessels that tumors need to grow and may kill cancer cells. It is a type of antiangiogenesis agent and a type of vascular endothelial growth factor (VEGF) receptor tyrosine kinase inhibitor.
The Mark Foundation Institute for Integrated Cancer Medicine (MFICM) at the University of Cambridge aims to revolutionise cancer care by affecting patients along their treatment pathway.
